Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.
Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide.
Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain.
Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.
A multi-institutional study reports an effective treatment approach to inhibit and keep latent viruses like herpes simplex from reactivating and causing disease. The work, whose lead author is the late James Hill, PhD, LSU Health New Orleans Professor and Director of Pharmacology and Infectious Disease at the LSU Eye Center, is published in the December 3, 2014, issue of Science Translational Medicine.
In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent.
Infection with herpes simplex virus increases the risk of Alzheimer's disease. Researchers at Umeå University, Sweden, claim this in two studies in the journal Alzheimer's & Dementia.
NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014.
In a study that included approximately 15,000 pregnant women, seroprevalence of herpes simplex virus (HSV) type 2 decreased substantially between 1989 and 2010 while there was no overall decrease for HSV type 1, but a slight increase among black women, according to a study in the August 20 issue of JAMA.
A rare procedure occasionally performed during Jewish circumcisions that involves direct oral suction is a likely source of herpes simplex virus type 1 (HSV-1) transmissions documented in infants between 1988 and 2012, a literature review conducted by Penn Medicine researchers and published online in the Journal of the Pediatric Infectious Disease Society found.
Researchers at the University of California, San Diego School of Medicine have identified the evolutionary origins of human herpes simplex virus (HSV) -1 and -2, reporting that the former infected hominids before their evolutionary split from chimpanzees 6 million years ago while the latter jumped from ancient chimpanzees to ancestors of modern humans - Homo erectus - approximately 1.6 million years ago.
PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.
Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV).
Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.
Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.
Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
Joseph C. Glorioso, III, PhD (University of Pittsburgh School of Medicine, PA) devoted much of his research career to developing herpes viruses as efficient vectors for delivering therapeutic genes into cells.
Admedus today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.
Dr. Beth Levine, a Howard Hughes Medical Institute Investigator and Director of the Center for Autophagy Research at UT Southwestern Medical Center, has received the 2014 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.